| Symbol | SABSW |
|---|---|
| Name | SAB BIOTHERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 777 W 41ST ST,SUITE 401, MIAMI BEACH, Florida, 33140, United States |
| Telephone | +1 305 - 845-2813 |
| Fax | — |
| — | |
| Website | https://www.sab.bio |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001833214 |
| Description | SAB BIO is a clinical-stage biopharmaceutical company working to treat and prevent immune and autoimmune disorders. Founded in 2014 and traded on NASDAQ (SABS) since 2021, SAB BIOs innovative genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma. The science behind the platform originated in 1998, and the company began its first clinical trials in 2017. To date, SAB BIO has conducted seven clinical trials that have dosed 700 individuals across multiple therapeutic areas. The safety and immunogenicity database for these trials shows zero patients with serum sickness or neutralizing anti-drug antibodies, which suggests an improved safety profile over other therapies. Additional info from NASDAQ: |
New Form 424B3 - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-21 <b>AccNo:</b> 0001193125-26-361180 <b>Size:</b> 159 KB
Read moreNew Form SCHEDULE 13G/A - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352646 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G/A - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001727492-26-000022 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001831942-26-000035 <b>Size:</b> 16 KB
Read moreNew Form SCHEDULE 13G/A - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001213900-26-090054 <b>Size:</b> 20 KB
Read moreNew Form SCHEDULE 13G/A - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000919574-26-005263 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003437 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13G - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000919574-26-004984 <b>Size:</b> 15 KB
Read moreNew Form SCHEDULE 13D/A - SAB Biotherapeutics, Inc. <b>Filed:</b> 2026-08-10 <b>AccNo:</b> 0001346824-26-000220 <b>Size:</b> 16 KB
Read moreSAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07670650 | PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Pepti… | Phase3 | Type 1 Diabetes (T1D) | Not_Yet_Recruiting | 2026-09-01 | 2030-09-01 | ClinicalTrials.gov |
| NCT07187531 | SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Pr… | Phase2 | Type 1 Diabetes | Recruiting | 2025-11-25 | 2028-12-01 | ClinicalTrials.gov |
| NCT06435936 | A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy… | Phase1 | PHA1A | Active_Not_Recruiting | 2024-04-22 | 2025-02-01 | ClinicalTrials.gov |
| NCT04850898 | Study of SAB-176 in Healthy Adult Participants | Phase2 | Influenza A H1N1 | Completed | 2021-06-23 | 2021-10-08 | ClinicalTrials.gov |
| NCT04469179 | Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participant… | Phase1 | COVID-19 | Unknown | 2020-08-20 | 2021-11-01 | ClinicalTrials.gov |
| NCT04471038 | Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants | Phase1 | Influenza Type A | Completed | 2020-07-29 | 2021-04-19 | ClinicalTrials.gov |
| NCT04468958 | Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants | Phase1 | COVID-19 | Completed | 2020-07-01 | 2020-12-23 | ClinicalTrials.gov |
| NCT02788188 | Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults | Phase1 | Middle East Respiratory Syndrome Coronavirus | Completed | 2016-05-28 | 2018-04-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Placebo | Other | Phase PHASE3 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07670650 |
| SAB-142 | Other | Phase PHASE3 | Type 1 Diabetes (T1D) | NOT_YET_RECRUITING | NCT07670650 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Normal (9%) Saline | Other | Phase PHASE1 | Middle East Respiratory Syndrome Coronavirus | COMPLETED | NCT02788188 |
| SAB-301 | Other | Phase PHASE1 | Middle East Respiratory Syndrome Coronavirus | COMPLETED | NCT02788188 |
| Normal Saline | Other | Phase PHASE1 | COVID-19 | UNKNOWN | NCT04469179 |
| SAB-185 | Other | Phase PHASE1 | COVID-19 | UNKNOWN | NCT04469179 |
| Normal saline | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04468958 |
| SAB-185 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT04468958 |
| Single Ascending Dose of Placebo | Other | Phase PHASE1 | PHA1A | ACTIVE_NOT_RECRUITING | NCT06435936 |
| Single Ascending Dose of SAB-176 | Other | Phase PHASE1 | PHA1A | ACTIVE_NOT_RECRUITING | NCT06435936 |
| Normal Saline | Other | Phase PHASE1 | Influenza Type A | COMPLETED | NCT04471038 |
| SAB-176 | Other | Phase PHASE1 | Influenza Type A | COMPLETED | NCT04471038 |
| Placebo | Other | Phase PHASE2 | Influenza A H1N1 | COMPLETED | NCT04850898 |
| SAB-176 | Other | Phase PHASE2 | Influenza A H1N1 | COMPLETED | NCT04850898 |
| Placebo | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | Other | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Low Dose SAB-142 | DRUG | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| High Dose SAB-142 | DRUG | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| Single Ascending Dose of Placebo | DRUG | Phase PHASE1 | PHA1A | ACTIVE_NOT_RECRUITING | NCT06435936 |
| Single Ascending Dose of SAB-176 | DRUG | Phase PHASE1 | PHA1A | ACTIVE_NOT_RECRUITING | NCT06435936 |
| Placebo | OTHER | Phase PHASE2 | Type 1 Diabetes | RECRUITING | NCT07187531 |
| SAB-176 | BIOLOGICAL | Phase PHASE2 | Influenza A H1N1 | COMPLETED | NCT04850898 |
| Normal Saline | OTHER | Phase PHASE1 | Influenza Type A | COMPLETED | NCT04471038 |
| Normal saline | OTHER | Phase PHASE1 | COVID-19 | COMPLETED | NCT04468958 |
| SAB-185 | BIOLOGICAL | Phase PHASE1 | COVID-19 | UNKNOWN | NCT04469179 |
| Normal (9%) Saline | OTHER | Phase PHASE1 | Middle East Respiratory Syndrome Coronavirus | COMPLETED | NCT02788188 |
| SAB-301 | BIOLOGICAL | Phase PHASE1 | Middle East Respiratory Syndrome Coronavirus | COMPLETED | NCT02788188 |